Regulation of energy metabolism through central GIPR signaling

Mar 25, 2024Peptides

Control of body energy use through brain GIP receptor signals

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Agonism and antagonism of the GIP receptor may improve metabolic outcomes when used alongside GLP-1 receptor agonism.

  • GLP-1 receptor agonism is widely recognized for its pharmacological benefits in combating obesity.
  • The role of the GIP system in metabolic regulation remains controversial, despite evidence supporting its beneficial effects.
  • Both GIP receptor agonism and antagonism have shown positive metabolic effects in preclinical and clinical studies.
  • There is accumulating evidence suggesting that GIP may have beneficial metabolic effects through its action in the brain.
  • Uncertainty exists regarding the specific locations and mechanisms of GIP action in the brain related to metabolism.

AI simplified

Full Text

Full text is available at the source.
View full text (XML) ↗View full text ↗

Related papers

Mar '24
Loss of GIP receptor in leptin receptor cells reduces glucose control by GIP and GIP-GLP-1 combination without changing body weight or food intake in mice
top 5% journal
cited by 11 papers
research support, non-u.s. gov't
Dec '18
Improved GIP-like drugs reduce body weight in mice by activating, not blocking, GIP receptors
top 5% journal
cited by 206 papers
research support, non-u.s. gov't
Dec '20
Targeting the GIP receptor for obesity: Should it be activated or blocked? Possible ways it works
top 5% journal
cited by 114 papers
research support, n.i.h., extramural
May '20
Drug effects of single, double, and triple peptide activators on GIP and GLP-1 hormone receptors
top 10% journal
cited by 51 papers
research support, non-u.s. gov't
Jul '24
How Incretin Hormones Help Regulate Heart Energy Use
cited by 1 paper
journal article
Feb '23
Fat around the human heart contains receptors for glucose-related hormones that could be targets for multiple treatments
top 5% journal
cited by 78 papers
research support, non-u.s. gov't
Sep '14
The GIP receptor is more active at rest than the GLP-1 receptor but less effective at attracting GRK2 or arrestin3 proteins
top 30% journal
cited by 47 papers
research support, non-u.s. gov't
May '16
Treating diabetes and obesity by activating two hormone receptors called 'twincretins'
cited by 53 papers
journal article

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
2 days ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
1 week ago7 studies
issue #33
Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes
2 weeks ago7 studies
issue #32
60% of weight lost on GLP-1 drugs returns within a year of stopping
3 weeks ago7 studies
issue #31
Semaglutide linked to 54% lower risk of new sleep apnea cases in 1.25 million patients
4 weeks ago7 studies
issue #30
Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity
5 weeks ago7 studies
issue #29
Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%
6 weeks ago7 studies
issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
7 weeks ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
8 weeks ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief